SCY-078 was initially discovered at the SCYNEXIS research facilities and developed as a result of a research collaboration with Merck. Subsequently, all worldwide intellectual property, development and commercialization rights were transferred to SCYNEXIS. We are currently developing this product as a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections.
In August 2013, we announced an agreement with R-Pharm CJSC, granting them exclusive rights to develop and commercialize SCY-078 in Russia, Turkey, and certain Balkan, Central Asian, Middle Eastern and Northern African countries. Invasive fungal infections are a serious health concern in these countries and we are pleased to be working with R-Pharm to develop SCY-078 for these patients.